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REVIEW
Safety of low dose glucocorticoid treatment in rheumatoid
arthritis: published evidence and prospective trial data
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Adverse effects of glucocorticoids have been abundantly
reported. Published reports on low dose glucocorticoid
treatment show that few of the commonly held beliefs about
their incidence, prevalence, and impact are supported by
clear scientific evidence. Safety data from recent
randomised controlled clinical trials of low dose
glucocorticoid treatment in RA suggest that adverse effects
associated with this drug are modest, and often not
statistically different from those of placebo.
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T
he introduction of glucocorticoids (GC) in
the 1950s was a revolution in the treatment
of a large variety of inflammatory diseases.
Enthusiasm generated by the dramatic results
led to the use of high doses, which disclosed a
spectrum of toxicity that shook the foundations
of this treatment. Despite this, GC still have a
pivotal role in the management of diverse
rheumatic conditions. The proportion of patients
treated with GC by practising physicians every
day is clearly in excess of the usually conserva-
tive recommendations in textbooks and review
papers. Recent studies demonstrating the disease
modifying potential of GC in lower dosages in
rheumatoid arthritis (RA) have renewed the
debate on the risk/benefit ratios of this treat-
ment. Arguments against GC use are dominated
by fear of a toxicity that is well engraved in
international medical culture but which is
strongly influenced by observations derived from
the use of high doses of GC. Whether this fear is
justified for lower dose treatment, specifically for
patients with RA, has not been completely
answered.
To examine this problem, a working party was
organised, comprising experts with a special
interest in this area, including rheumatologists
and one endocrinologist from Europe and
America, with representation of most groups
that have conducted randomised clinical trials on
the use of GC in RA. The panel agreed to perform
two major tasks and the results of these are
presented in this paper:
N A literature review of the adverse effects of long term
low dose GC, especially in rheumatic diseases. The
group compiled an extensive and comprehen-
sive list of all putative adverse effects attrib-
uted to GC by a primary search of textbooks
and review papers. This list was split into
categories similar to those in this text. As a
first step, for each category a thorough search
was performed, using the adverse effects as
keywords and the reference lists of the
original papers. This literature was reviewed
and described; the texts produced were
circulated numerous times among all mem-
bers of the group for critical appraisal of
completeness and balance. Given that the vast
majority of available data on GC is observa-
tional and retrospective and refers to diverse
diseases, doses, and regimens, appreciation of
the level of evidence was frequently difficult
and subjective. This was resolved by reviewing
the underlying data and discussion, until
consensus was achieved.
N An analysis of toxicity data from the randomised
controlled trials of GC in RA. As the working
party comprised of representatives of all
groups who had conducted 2 year trials on
the use of GC in RA, very detailed information
on adverse effects from these trials was
available for discussion. Differences in method-
ology precluded a systemic meta-analysis of the
adverse effects observed. Here, results from each
trial, where available, are summed. The data
incorporated in this review come from the
following trials: the Arthritis and Rheumatism
Council Low-Dose Glucocorticoid Study, here
further designated as the ACR study,1 2 the
German study, here further designated as the
LDPT (low dose prednisolone therapy) study,3
the Utrecht study,4 and WOSERACT5 (table 1).
Although the proposed definition of ‘‘low dose’’
is 7.5 mg prednisolone equivalent or less, to
enhance readability these four trials as a group
are in this paper described as ‘‘the four
extensively reviewed trials on low dose GC in
RA’’. More details on these trials are available
through hyperlinks to the electronic version of
this article on the website of the Annals
(hyperlink 1, http://www.annrheumdis.com/
supplemental). Previously unpublished detailed
monitoring results from the ‘‘combination
treatment in early rheumatoid arthritis’’
(COBRA) trial are included in the web version
of this paper (hyperlink 2, http://www.
annrheumdis.com/supplemental).
Abbreviations: BMD, bone mineral density; COBRA,
combination treatment in early rheumatoid arthritis (trial);
GC, glucocorticoid(s); GI, gastrointestinal; NSAIDs, non-
steroidal anti-inflammatory drugs; RA, rheumatoid
arthritis; SLE, systemic lupus erythematosus
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This paper is the result of these efforts. It gives a critical
and pragmatic overview of scientific evidence on the adverse
effects of chronic GC treatment in lower dosages ((10 mg/
day prednisolone equivalent) in RA in daily clinical practice.
MUSCULOSKELETAL ADVERSE EFFECTS
Osteoporosis
Osteoporosis is a well established side effect of chronic GC
use. The incidence of osteoporosis is time and dose
dependent, but there is no consensus about a ‘‘safe’’ dose.
Although some studies suggest that doses of 7.5 mg of
prednisone a day or less are relatively safe, a longitudinal
study observed an average loss of 9.5% from spinal trabecular
bone over 20 weeks in patients exposed to 7.5 mg of
prednisolone a day.6–8 Studies focusing on low dose treatment
are relatively scarce, however. Further, it is important to
recognise that in non-randomised studies, factors such as
age, underlying disease, disease severity, co-medication, and
duration of treatment can lead to confounding by indication
for GC, and may thus preclude definite conclusions. Alternate
day GC regimens have not been shown to reduce bone loss.9 10
In 1997, an exhaustive literature search for all prospective
studies found only 18 studies and 329 patients in whom bone
mass was studied prospectively while receiving GC treatment
for any disease.11 An update of this review now includes
almost 1200 patients.12 At a mean dose of almost 9 mg
prednisone equivalent a day, the best estimate of bone loss
overall in spine and hip (without bisphosphonate treatment)
is 1.5% a year. Important positive predictive factors include
starting dose and chronic usage; and in the spine, dose and
lack of vitamin D supplementation.
‘‘Chronic use of glucocorticoids doubles the already
increased risk of osteoporosis in RA’’
The consequences of this bone mass loss upon fracture rate
proved to be quite significant. Although the underlying
disease itself, such as RA, may be associated with an
increased incidence of osteoporosis or falls, the chronic use
of GC further amplifies this increased risk by a factor of 2.13 14
In a recent multicentre cross sectional study, 205 patients
with RA who were receiving daily GC orally were compared
with 205 matched patients who did not receive GC. Vertebral
deformities were found in 25% of patients receiving GC
compared with 13% of controls. The occurrence of vertebral
deformities was dose dependent.7
In a recent retrospective cohort study using the General
Practice Research Database of the UK it was shown that the
rate of clinical vertebral fractures increased by 55% for a dose
of prednisolone of less than 2.5 mg/day and by over 400% if
the dose exceeded 7.5 mg/day.15 Inflammatory disease
activity has been shown to be an independent risk factor
for osteoporosis, at least in RA. Disease activity leads to
reduced physical activity and increased levels of inflamma-
tory cytokines, such as tumour necrosis factor a, which
stimulate differentiation of osteoclasts both directly and
indirectly via RANK ligand (osteoclast differentiation factor)
and thus lead to bone loss. Possibly, therefore, GC in RA,
leading to decreased disease activity, may cause less bone loss
than they would have in the absence of inflammatory
disease. Studies disagree as to whether a cumulative dose
is,8 16 or is not15 17 associated with a degree of bone loss. A
recent study showed that the greatest increase in the risk of
vertebral fractures induced by GC was seen in older
postmenopausal women, age being a risk factor independent
of bone mineral density (BMD).18 On the other hand, it is
quite likely that, as some studies suggested, fractures occur at
higher BMD levels in patients treated with GC than in
patients not treated with GC.19
Data from the four extensively reviewed trials on low dose
GC in RA showed that BMD loss over 2 years of low dose
prednisone is not significantly different from that with
placebo (hyperlink 1, http://www.annrheumdis.com/supple-
mental). The higher doses of prednisone used in the COBRA
study were associated with a higher BMD loss,20 but this
difference did not reach statistical significance either
(hyperlink 2, http://www.annrheumdis.com/supplemental).
Fracture incidences were similar in both groups in the LTDP
study.3 However, the Utrecht group found twice the incidence
of radiological vertebral fractures in the prednisone group,
but this did not reach statistical significance.4
Osteoporosis is probably the most common adverse effect
of chronic low dose GC but fortunately is preventable.
Strategies for the prevention and treatment of GC-induced
osteoporosis are well established and have been the object of
recent extensive reviews,19 21 22 and authoritative guidelines.23–25
Osteonecrosis
Osteonecrosis (avascular necrosis of bone) has been, for a
long time, considered an important consequence of high dose
GC use. In a Japanese study of osteonecrosis of the femoral
head, 35% of all cases were related to GC treatment.26
However, it is sometimes difficult to know whether the
treatment or the underlying disease is the cause, because
some conditions, such as systemic lupus erythematosus
(SLE), are associated with an increased risk of osteonecro-
sis,27 especially in young patients with several organs
affected. This is one of the reasons why some authors
question the evidence that GC are actually responsible for
osteonecrosis.28 Although the occurrence of GC related
osteonecrosis seems to be dose dependent, this might be
confounded by the fact that higher doses are related to more
severe underlying disease and increased risk of osteonecrosis.
One study reported osteonecrosis in 2.4% of patients
receiving GC replacement treatment,29 but data on low dose
GC treatment are scarce and mostly anecdotal. At least in
SLE, a higher average dose may be a more important
Table 1 Characteristics of the four extensively reviewed rheumatoid arthritis trials using
(10 mg prednisone daily
Study ARC study LDPT study Utrecht study WOSERACT
Year of first publication 1995 2000 2002 2004
Reference 1, 2 3 4 5
RA duration at entry (years) ,2 ,2 ,1 Median 1
Number of patients,
prednisolone group
61 34 40 84
Prednisolone dose/day (mg) 7.5 5 10 7
Duration of trial (years) 2 2 2 2
Associated DMARDs Various IM gold or MTX Sulfasalazine
rescue
Sulfasalazine
DMARDs, disease modifying antirheumatic drugs; IM, intramuscular; MTX, methotrexate.
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predictor of avascular necrosis of bone than the cumulative
dose.30 No case of avascular necrosis was seen either in the
four extensively reviewed trials on low dose GC in RA or in
the COBRA trial (hyperlinks 1 and 2, http://www.annrheum-
dis.com/supplemental).
Many crucial questions in this area remain unanswered—
namely, questions about the relevance of the dose, route of
administration, and duration of GC treatment, as well as the
host factors that modulate the risk. In the meantime, it is
generally accepted that in patients treated with low doses of
GC, osteonecrosis is uncommon. Primary prevention is not
really possible; awareness should be increased.31
Myopathy
Remarkably, a search of the literature showed an absence of
data on, and proper studies of, myopathy. A recent review on
this subject supports this contention.32 Based on the scarce
information available and our own experience, we believe
that myopathy is exceedingly rare with GC doses of ,7.5 mg
prednisolone equivalent daily. Chronic steroid myopathy is
quite often suspected, but not often found or documented.
The clinical picture can be difficult to distinguish from the
effects of the underlying disease, especially in the case of
musculoskeletal conditions, such as myositis or inflammatory
arthritis.33 On electromyographic examination no sponta-
neous electrical activity is found; the serum aldolase and
creatine kinase level are normal, but creatinuria may be
increased. These findings are considered suggestive of steroid
myopathy.34 Diagnosis can be ascertained by muscle biopsy,
showing atrophy of type II fibres, and absence of inflamma-
tion. There are no real preventative or individual risk factors
to be evaluated; awareness will facilitate early recognition of
this problem. No cases of myopathy were seen in the four
extensively reviewed trials on low dose GC in RA (hyperlink
1, http://www.annrheumdis.com/supplemental).
ENDOCRINE AND METABOLIC ADVERSE EFFECTS
Glucose intolerance and diabetes
GC increase serum glucose levels through an increase in
hepatic glucose production and changes in insulin production
and resistance.35–40 In patients without pre-existing abnorm-
alities of glucose tolerance, GC cause slightly increased
fasting glucose levels and a more pronounced increase of
postprandial values. The increment follows a similar pattern
in diabetic patients but tends to be more pronounced in
longstanding diabetes.41 42
GC related hyperglycaemia is dose dependent. However,
low dose GC also have this effect. One case-control study
suggested an increased risk (odds ratio = 1.8) for initiation of
anti-hyperglycaemic drugs during GC treatment using 0.25–
2.5 prednisone equivalent a day.43 Hyperglycaemia can also be
observed after intra-articular GC.44 It is likely that subjects
with risk factors for the development of diabetes mellitus,
such as a family history of this disease, increasing age,
obesity, and previous gestational diabetes mellitus, are at
increased risk of developing new onset hyperglycaemia
during GC treatment.41 This is usually rapidly reversed when
GC are stopped, but some patients will go on to develop
persistent diabetes.45
Next to the average daily dose, the type of GC is of great
importance. Dexamethasone is 30 times and prednisone four
times as potent as hydrocortisone in the impairment of
glucose metabolism.46 The suggestion that deflazacort may be
less prone to cause hyperglycaemia than prednisone must be
questioned based on the probably inadequate correction for
glucocorticoid potency.47
Data from the four extensively reviewed trials on low dose
GC in RA are quite reassuring in this respect: no cases of new
onset diabetes were seen in either of the studies. The Utrecht
trial found the least favourable results4: a significant increase
in mean (SD) fasting glucose was seen in the prednisone
group (from 5.1 (0.6) at baseline to 5.9 (1.9) mmol/l at
2 years, p = 0.01). However, even in this study, hyperglycae-
mia, as defined by the World Health Organisation, developed
in only two patients in the prednisone group (n = 40) and
one in the placebo group (n = 41) (hyperlink 1, http://
www.annrheumdis.com/supplemental).
There are no preventive measures apart from the use of
lower doses of GC. Alternate day treatment is associated with
alternate day hyperglycaemia.48
In patients with insulin dependent diabetes exposed to
very high doses of GC after kidney transplantation, an insulin
dose 58% higher than in those not receiving GC was
necessary.49 50 We could find no studies on the specific effects
of low dose GC in diabetic patients. A relevant and detailed
discussion of glucose control under GC treatment has been
published.42
Fat redistribution and body weight
One of the most notable effects of chronic endogenous and
exogenous GC excess is the redistribution of body fat.
Centripetal fat accumulation with sparing of the extremities
is a characteristic feature of patients exposed to long term
high dose GC. It is seen even with low dose GC. Potential
mechanisms include hyperinsulinaemia, changes in expres-
sion and activity of adipocyte derived hormones and
cytokines, such as leptin and tumour necrosis factor a,
increased food intake (GC increase appetite), and muscle
atrophy.51–55
Our own review of toxicity data from the four RA
prospective trials shows that low dose prednisone is
associated with an increase of mean body weight over
2 years, in the range of 4–8%. In two of these trials, this
weight gain was significantly higher than in the placebo
group3 4 These observations were confirmed in the COBRA
trial, but the differences were nullified after prednisone was
stopped. However, patients in the control groups also gained
weight (hyperlinks 1 and 2, http://www.annrheumdis.com/
supplemental).
Suppression of sex hormone secretion
GC in high doses decrease gonadotropin-releasing hormone
(GnRH) secretion from the hypothalamus, decrease basal and
GnRH-stimulated luteinising hormone secretion from the
pituitary, and decrease the responsiveness of gonadal cells to
luteinising hormone, leading to lower levels of oestrogens56
and testosterone.57 58 This latter effect predominates in men.59
These suppressing effects can contribute to steroid-induced
osteoporosis. Despite these observations, it has been sug-
gested that glucocorticoid treatment in rheumatic diseases
does not cause a clinically relevant adverse effect on
fertility,60 and decreased libido has not been reported as a
common complaint in patients exposed to low dose GC. In
the four extensively reviewed trials on low dose GC in RA,
decreased libido was not reported spontaneously.
CARDIOVASCULAR ADVERSE EFFECTS
Dyslipidaemia, atherosclerosis, and cardiovascular
disease
GC treatment is considered to be a risk factor for dyslipidae-
mia and atherosclerosis.61–64 Several studies in patients with
SLE suggest that GC treatment is dose dependently asso-
ciated with hypercholesterolaemia: significant changes were
seen only at prednisone doses higher than 10 mg/day.65–67
Beyond induction of dyslipidaemia, the role of GC in
atherosclerosis is controversial. Longer steroid use is sig-
nificantly associated with coronary artery disease in patients
with SLE.68–70 Also a study in patients with RA suggested that
Safety of low dose glucocorticoids in RA 287
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GC treatment early in the disease course increased the risk of
coronary artery disease.71 On the other hand, in a study using
an animal model of atherosclerosis,72 although administra-
tion of dexamethasone induced hyperlipidaemia, it also
reduced aortic plaque formation, an effect attributed to
inhibition of infiltration of inflammatory and foam cells in
the plaques. The recognition of an association between raised
C reactive protein and accelerated coronary artery disease
offers a theoretical basis for GC benefit on atherosclerotic
disease in inflammatory diseases.73 Furthermore, recent data
from cohorts show that RA disease activity unfavourably
alters the blood lipid profile, and that treatment (including
GC treatment) can reverse these changes.74 In the four
extensively reviewed trials on low dose GC treatment in RA,
lipids were not routinely assessed.
‘‘Evidence is lacking to show that low dose GC, unlike high
dose GC, significantly increase the incidence of cardio-
vascular disease in RA’’
Recently, a record linkage database study on 68 781 GC
users (of whom 1115 patients had RA) and 82 202 non-users
was published.75 The incidence of all cardiovascular diseases,
including myocardial infarction, heart failure, and cerebro-
vascular disease, was not increased in patients using
,7.5 mg/day prednisolone long term. However, it was
increased in patients using doses >7.5 mg daily: relative risk
adjusted for all known risk factors 2.6, 95% confidence
interval 2.2 to 3. In the four extensively reviewed trials on low
dose GC treatment in RA and in the COBRA trial, no excess
cardiovascular events were reported, but the trial duration of
2 years was relatively short for development of these
complications.
In summary, the evidence does not support a significant
role for low dose GC treatment on the development of
cardiovascular disease in RA, in contrast with higher doses.
In patients with RA receiving low dose GC, the disease itself
seems to be a greater risk factor.
Water and electrolyte balance, oedema, renal and
heart function
Hypernatraemia, hypokalaemia, and sodium and water
retention are mineralocorticoid effects, produced by endo-
genous GC at supraphysiological concentrations.76 These
effects may lead to oedema and contribute to hypertension
and heart failure in patients with Cushing’s disease.
However, synthetic GC (prednisone, prednisolone, methyl-
prednisolone, dexamethasone) have little mineralocorticoid
effects, and their administration increases the glomerular
filtration rate and induces kaliuresis and natriuresis without
any change in plasma volume.77–86 A small number of trials
have evaluated chronic GC administration in moderate to
high doses in patients with heart failure, and no significant
detrimental effect on heart function emerged from these
studies.87 88 In the four extensively reviewed trials on low dose
GC treatment in RA as well as in the COBRA trial, no cardiac
insufficiency attributable to GC occurred.
Hypertension
Induction of hypertension is a well demonstrated adverse
effect of GC, seen in about 20% of patients exposed to
exogenous GC.89 The mechanisms involved have not been
fully elucidated.90 A retrospective study of 195 patients with
RA or asthma undergoing GC treatment with ,20 mg/day
prednisone for longer than a year,91 did not show any
correlation between dose or duration of GC treatment and
rise in blood pressure.
Toxicity data from the four extensively reviewed trials on
low dose GC in RA are very reassuring about the effect on
blood pressure: prednisone had no significant effects on
blood pressure in any of the trials. During the first phase of
the COBRA trial, the mean blood pressure was at some time
points higher in the prednisone than in the placebo group,
but high to medium doses of GC were used. Note that
patients with severe hypertension were excluded from
most of these trials (hyperlinks 1 and 2, http://www.
annrheumdis.com/supplemental).
These results suggest that glucocorticoid-induced hyper-
tension is dose related and is less likely with medium or low
dose treatment. Individual variation in susceptibility and
other factors, such as the basal level of blood pressure, diet
salt, functional renal mass, associated diseases, and drug
treatment, may have a role in the development of glucocorti-
coid-induced hypertension.89 Some authors suggest that the use
of alternate day regimens may reduce the tendency towards
blood pressure increase,92 but evidence for this is weak.
Other cardiac adverse effects
Incidences of arrhythmia93 and sudden death are rare and
mostly limited to patients receiving high dose pulse GC.94 95 In
the four extensively reviewed trials on low dose GC treatment
in RA and in the COBRA trial, these events were not reported.
DERMATOLOGICAL ADVERSE EFFECTS
Clinically relevant adverse effects on the skin include
iatrogenic Cushing’s syndrome, catabolic effects (cutaneous
atrophy, purpura, striae, easy bruisability, and impaired
wound healing), steroid acne, and hair effects.96 Cushingoid
phenotype is seen in over 5% of the patients exposed to
>5 mg prednisone equivalent for >1 year.97–99 The incidence
of iatrogenic Cushing’s syndrome is dose dependent and, in
general, becomes evident after at least 1 month of GC
treatment.96 Some authors suggest that alternate day admin-
istration decreases the development of cushingoid features,100
but this has not been clearly established.
Catabolic effects on the skin may appear during local and
systemic GC treatment. Cutaneous atrophy mainly results
from the effect of GC on keratinocytes and fibroblasts.
Decreased vascular structural integrity is probably a key
determinant of purpura and easy bruisability in GC treated
patients.101 These effects were reported to affect over 5% of
those exposed to >5 mg prednisone equivalent a day for >1
year.97 102 103 Wound healing impairment seems uncommon at
low dose, but there are no exact data on prevalence. There are
no data on the incidence of steroid acne and hair effects like
hirsutism and hair loss, but they are more common with long
term treatment with medium to high doses of GC, such as
those used after organ transplantation.96 These effects of GC
may sometimes be difficult to separate from those of the disease
itself (for example, hair loss in SLE) and other medications.
Most of the cutaneous adverse effects of GC are not
considered serious by the doctor, but they may represent a
considerable cosmetic problem for the patient. Available data
suggest that these effects are relatively uncommon and of
minor clinical concern with low dose GC treatment, although
data on incidence are scarce. There is no strong evidence to
support the claim that use of the lowest possible dose and
alternate day treatment may fully prevent these adverse
effects. In the four extensively reviewed trials on low dose GC
treatment in RA and in the COBRA study, serious cutaneous
adverse effects were not reported, but the trial duration was
relatively short for development of these complications.
OPHTHALMOLOGICAL ADVERSE EFFECTS
Cataract
Long term use of systemic GC may induce formation of
posterior subcapsular cataract, characterised by disruption of
the ordered maturation of the lens fibres, which then
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www.annrheumdis.com
 on 27 November 2008 ard.bmj.comDownloaded from 
accumulate on the front surface of the posterior lens capsule.
Cortical cataracts have also been attributed to GC.104
Reports on the incidence of cataract with long term low
dose systemic GC treatment are scarce. In a group of patients
with RA treated with 5–15 mg/day prednisone (mean (SD) 6
(3) mg/day) for a mean (SD) of 6 (5) years, 15% were found
to have cataracts, compared with 4.5% of matched RA
controls not using prednisone.14 There is no evidence that
alternate day treatment reduces the risk.105 Cataract forma-
tion is considered to be irreversible. We could find no
evidence of the possibility of halting progression by reducing
the dose or interrupting treatment. More careful prospective
assessment of cataract formation among GC users is needed
to answer this question definitively. In the four extensively
reviewed trials on low dose GC treatment in RA and in the
COBRA study, excess cataracts were not reported, but the
trial duration was probably too short for development of this
complication and only two of the four extensively reviewed
trials on low dose GC treatment in RA included a regular
ophthalmological check in a significant number of patients.
Glaucoma
Systemic GC increase the risk of glaucoma and may result in
visual field loss or even blindness. In the general population,
18–36% of those exposed to GC had an increase in intraocular
pressure.106 Open angle glaucoma was found in 6/32 (19%)
rheumatic patients exposed to >7.5 mg/day prednisone
equivalent for more than 1 year and in 1/38 (3%) patients
treated with ,7.5 mg/day prednisone equivalent (Tryc A,
Bartholome B, Buttgereit F, et al, unpublished data).
However, the occurrence and magnitude of the increase in
intraocular pressure with GC administration are highly
variable between patients.107 A high incidence of this adverse
effect with GC use tends to occur in families, suggesting a
genetic basis.108 Patients with pre-existing glaucoma are
especially sensitive: 46–92% of patients with open angle
and 65% of those with closed angle glaucoma will have this
condition aggravated upon exposure to GC.106 109 Patients
with diabetes mellitus, high myopia, and relatives of those
with open angle glaucoma are reported to be more vulnerable
to GC-induced glaucoma.106 A rise in intraocular pressure
with exogenous GC is generally reversible when treatment is
stopped, although it may take several weeks. Medications
that lower intraocular pressure may control even a significant
pressure increase induced by concomitant GC.110 As glaucoma
often is asymptomatic and can lead to severe loss of sight,
regular eye pressure checks are recommended for patients
receiving high dose long term systemic GC treatment,
especially for those with associated risk factors for glaucoma.
For patients receiving low dose GC treatment and who have
no additional risk factors for glaucoma, it is generally stated
that routine checks seem not to be indicated. Only two of the
four extensively reviewed trials on low dose GC treatment in
RA included a regular ophthalmological check in a significant
number of patients. However, these checks suggest an
increased risk of glaucoma with prednisone (hyperlink 1,
http://www.annrheumdis.com/supplemental).
GASTROINTESTINAL ADVERSE EFFECTS
Peptic ulcer disease
The association between GC use and the risk of peptic ulcer
disease has been the subject of extensive debate and
contradictory evidence.111–113 The influence of the underlying
disease on the risk of peptic ulceration is difficult to isolate.
Piper et al performed a nested control study including 1415
patients admitted to the hospital for gastroduodenal ulcer or
haemorrhage and 7063 randomly selected controls from
Medicaid.114 The overall estimated relative risk for peptic ulcer
disease among current GC users was 2.0 (95% CI 1.3 to 3.0).
However, this increased risk was almost completely due to
co-treatment with non-steroidal anti-inflammatory drugs
(NSAIDs): the relative risk for patients co-medicated with
NSAIDs was 4.4 (95% CI 2.0 to 9.7), but for those receiving
only GC there was no significant increase in risk: 1.1 (95% CI
0.5 to 2.1). In large scale studies based on the UK General
Practice Research Database,115 the relative risk of upper
gastrointestinal (GI) complications was 1.8 (95% CI 1.3 to
2.4) for users of GC compared with non users. The risk
tended to be greater for higher GC doses, but this trend was
not statistically significant. The risk was shown to be more
than 12 times higher for concomitant users of both GC and
NSAIDs than for non-users of either drug. Data from the four
RA prospective trials and the COBRA study show no
increased incidence of upper GI ulcers and bleeds, but these
events are relatively uncommon and may not be detected in
these clinical trials with a relatively low number of
participating patients (hyperlink 1, http://www.annrheum-
dis.com/supplemental). In patients treated with GC without
concomitant use of NSAIDs there thus seems to be no
indication for gastroprotective agents if there are no (other)
risk factors for peptic complications.
Pancreatitis
Although GC are usually listed as one of the many potential
causes of pancreatitis, evidence for such an association is
weak and difficult to separate from the influence of the
underlying disease, such as SLE or vasculitis. Experimental
and postmortem studies suggest that GC use is associated
with an increased incidence of pancreatitis. In one post-
mortem study, acute pancreatitis or fat necrosis was seen in
29% of those treated with adrenocorticotropic hormone or GC
compared with 4% in the controls.116 However, none of these
patients had been diagnosed with pancreatitis premortem,
suggesting that clinically relevant pancreatitis due to GC is
rare. Controlled studies showed that GC treatment does not
cause an increased incidence of pancreatitis in patients with
SLE.117 In the four extensively reviewed trials on low dose GC
treatment in RA and in the COBRA study, no case of
pancreatitis was reported.
INFECTIOUS ADVERSE EFFECTS
The use of GC is associated with increased susceptibility to
various viral, bacterial, fungal, and parasitic infections. The
mechanisms underlying this effect are manifold and not
completely understood.118 Most of these mechanisms, such as
the decrease in function of monocytes, subside rapidly when
treatment is interrupted, an observation that may explain the
lower infectious risk with the use of short acting GC and
alternate day treatment.119 120 The risk of infection increases
with dose and duration of treatment,121 and tends to remain
low in patients exposed to low doses, even with high
cumulative dosages.122 In a meta-analysis of 71 trials
involving over 2000 patients with different diseases and
different dosages of GC, a relative risk of infection was found
of 2.0.123 Five of these 71 trials involved patients with
rheumatic diseases and showed no increased relative risk. In
two studies specifically on RA the incidence of serious
infections was found to be similar to that of placebo or only
slightly increased.4 14 SLE is associated with an increased risk
of opportunistic infections, exacerbated by treatment with
GC.124 125 Of the intensively reviewed four studies of low dose
GC treatment in RA, both in the Utrecht and the WOSERACT
trials, prednisone up to 10 mg/day was not associated with
increased incidence of any kind of infections over the 2 years
of the trials.4 5
In patients treated with GC, physicians should anticipate
the risk of infections with both usual and unusual organisms,
realising that GC may blunt the classic clinical features and
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delay the diagnosis. Under special clinical circumstances and
in severely immunocompromised patients it may be wise to
screen for latent infections, such as tuberculosis, or institute
prophylactic chemotherapy.122 Pneumocystis carinii infections
deserve special attention, as doses as low as 16 mg/day
prednisone for 8 weeks have been associated with increased
risk in one series.126
PSYCHOLOGICAL AND BEHAVIOURAL
DISTURBANCES
Steroid psychosis
Psychosis is characterised by hallucinations, delusions, or
both. Reported estimates of the incidence of steroid psychosis
vary greatly (0–60%), owing to differences in study groups
and methodology of assessing this adverse event. Following
an authoritative review, the estimate of incidence of 5–6%
has become consensual in the literature.127 However, most
cases are associated with high doses of GC and an influence
of the underlying disease, such as SLE, is often difficult to
exclude. A landmark study in this area is the Boston
Cooperative Drug Surveillance Program.128 The incidence of
steroid psychosis in 718 prednisone treated patients was 1.3%
at 40 mg daily, 4–5% at 41–80 mg/day, and .18% with
higher doses. Several studies examining doses of (20 mg did
not find cases of psychosis.129 This adverse event was not
reported either in the four extensively reviewed trials on low
dose GC treatment in RA, or in the COBRA study.
‘‘Psychosis induced by glucocorticoids is rare with low
dose regimens’’
Thus the clinician should be aware of this adverse effect
and its clinical features,130 131 but overt psychosis is extremely
rare with the low and medium dose regimens usually
employed in rheumatology.
Minor mood disturbances
GC treatment has been associated with a variety of low grade
disturbances such as depressed or elated mood (euphoria),
irritability or emotional lability, anxiety and insomnia,
memory and cognition impairments. The exact incidence of
such symptoms in rheumatic patients exposed to common
doses of GC cannot be drawn from the literature. Most
studies relate to doses of 80–160 mg of prednisone equivalent
a day, far exceeding common long term regimens in
rheumatology.132 Evidence for minor effects is scarce, but
doses of ,20–25 mg prednisone equivalent a day are
associated with few or no significant disturbances.133 134
However, individual susceptibility is highly variable and in
a few published cases a relationship between low dose GC
and even topical steroids and psychotic episodes seems hard
to doubt. These adverse events were not reported or system-
atically assessed in the four extensively reviewed trials on low
dose GC treatment in RA, or in the COBRA study.
DRUG INTERACTIONS
Significant interactions between GC and other prescription
treatments have been well documented. Drugs that reduce the
systemic GC concentration may diminish clinical efficacy.
They include large doses of aluminium/magnesium hydro-
xide, which decrease prednisone bioavailability by 30–
40%,135 136 and most anticonvulsant drugs (for example,
phenobarbital, phenytoin), which enhance the metabolism
of GC.137–142 Rifampicin accelerates the metabolism of
synthetic GC, as may St John’s wort.143 Non-responsiveness
of inflammatory diseases to prednisone, induced by rifampi-
cin, has been described and rifampicin-induced adrenal crisis
in patients receiving GC replacement treatment has been
documented.144–147
Drugs that raise the systemic GC concentration include
some oral contraceptives,148–151 antibiotics (erythromycin and
troleandomycin).152–154 Antifungal agents, particularly keto-
conazole decrease GC metabolising enzymes.155 156 Some data
suggest that several NSAIDs, including indometacin and
naproxen, increase GC concentrations.157 Conversely, GC may
affect serum concentration, efficacy, or toxicity of other
drugs, such as warfarin and salicylates.158 159 In addition,
when used concomitantly with traditional NSAIDs, GC cause
an increased risk of upper GI adverse events, particularly in
patients with RA (see above).115 160
Neither the four extensively reviewed trials on low dose GC
treatment in RA, nor the COBRA study, were adequate to
study these interactions.
CONCLUSIONS AND RESEARCH AGENDA
After a careful literature review of the adverse effects of low
dose GC, an extensive review of the adverse effects of four
trials on low dose GC treatment in RA and the COBRA study,
and extensive group discussions, our main conclusion is that
definitive associations of low dose GC with many adverse
effects remain elusive. The overall fear of GC toxicity in RA,
as quoted in textbooks and review articles, is probably
overestimated, based on extrapolation from observations
with higher dose treatment. The balance of risks and benefits
of low dose treatment clearly differs from that of medium
and high dose treatment, for which the mechanisms of action
of GC may be different.161 This may explain why GC are used
in practice in more patients than the more pessimist
recommendations suggest. Physicians, and probably patients,
seem to value the benefit/risk ratio of low dose GC. The
evidence on which to support clear recommendations about
toxicity of low dose GC is surprisingly weak. The literature
and the recent trial results suggest that routine toxicity
monitoring for patients receiving low dose GC is not currently
justifiable or cost effective based on existing evidence.
However, patients with additional risk factors (for example,
osteoporosis, obesity, hypertension, a family history of
diabetes or glaucoma) merit more careful observation
(table 2).
GC will probably be used with enormous therapeutic value
in the treatment of a large variety of rheumatic conditions for
many years to come, especially because it becomes increas-
ingly clear that they have disease modifying potential. The
data reported in this paper of trials not primarily designed for
assessment of adverse effects and of observational studies
with possible bias, especially confounding by indication, do
not represent the highest level of evidence. So the safety of
low dose GC also needs to undergo serious and systematic re-
evaluation with properly designed and dedicated studies of
adequate size, duration, and using state of the art end points.
Guidelines for such studies would enhance comprehensive-
ness and comparability. We believe the areas listed in table 2
should be further explored when new studies of low dose GC
are undertaken, and physicians might wish to consider these
issues in clinical practice when prescribing GC treatment.
Table 2 Glucocorticoid related adverse effects other
than osteoporosis that may justify regular checks
l Cushingoid symptoms
l Adrenal crisis on glucocorticoid withdrawal
l Growth retardation in children
l New onset of diabetes mellitus in subjects at risk for developing DM
l Worsening of glycaemia control in patients with diabetes mellitus
l Cataracts and glaucoma
l Peptic ulcer (in combination with NSAIDs)
l Hypertension
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Furthermore, subjects participating in randomised clinical
trials may not have the same disease characteristics or
comorbidities as patients treated in the community, thereby
limiting the generalisability of findings of this kind of trial.162
So, simple, pragmatic trials with appropriate patient selection
and sufficiently long duration are also needed.
Other areas of research include the best timing of
administration, the potential advantages and limitations of
alternate day dosing, identification of risk factors for such
adverse effects as upper GI complications, glaucoma,
cataract, and studies of the individual sensitivity to GC
related to underlying mechanisms, such as receptor gene
polymorphisms.163 Elucidation of the biological mechanisms
involved in these effects will open new opportunities for
prevention and treatment. Research on the potential separa-
tion of wanted from unwanted GC effects using newly
designed GC-type medicine provides good reason to hope that
an even better safety/efficacy ratio can be achieved in the
future.164
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